A 24-year-old woman (53 kg) with a 5-year history of steroid-dependent ulcerative colitis with mild and extensive ulcerations presented to the gastroenterology clinic for symptom recurrence. She was given 100 mg/day (1.9 mg · kg−1 · day−1) azathioprine (AZA)5 for 1 month, after which the dose was increased to 125 mg/day (2.3 mg · kg−1 · day−1).
Student Discussion Document (pdf)
Laurent Chouchana,1,2,3 Denis Roche,1 Raymond Jian,2,4 Philippe Beaune,1,2,3 and Marie-Anne Loriot1,2,3*
1Assistance publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Biochimie, Pharmacogénétique et
Oncologie Moléculaire, Paris, France; 2Université Paris Descartes, Sorbonne Paris Cité, Paris, France; 3INSERM UMRS775,
Paris, France; 4Assistance publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Hepato-gastroenterologie
et endoscopie digestive, Paris, France.
*Assistance publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Biochimie, Pharmacogénétique et
Oncologie Moléculaire, 20 rue Leblanc, Paris, France. Fax: +33-1-56-09-33-93;
A 24-year-old woman (53 kg) with a 5-year history of steroid-dependent ulcerative colitis
with mild and extensive ulcerations presented to the gastroenterology clinic for symptom
recurrence. She was given 100 mg/day (1.9 mg · kg-1 · day-1) azathioprine (AZA) for 1
month, after which the dose was increased to 125 mg/day (2.3 mg · kg-1 · day-1). Four
months later, the patient was tapered off steroid therapy. Her symptoms persisted after 7
months of AZA therapy, however, and she experienced gastrointestinal side effects. The
patient was switched to another thiopurine drug, 6-mercaptopurine (6-MP), at 75 mg/day
(1.4 mg · kg-1 · day-1), which was well tolerated but similarly ineffective (8 stools daily).
A brief course of steroid therapy rapidly produced a substantial but short-lived clinical
To understand this patient’s unresponsiveness to 2 thiopurine agents, we quantified
thiopurine metabolites (1) 1 year after initiating AZA therapy. Intraerythrocyte
concentrations of 6-thioguanine nucleotides (6-TGNs) were low (132 pmol/8 · 108
erythrocytes; therapeutic interval, 230–400 pmol/8 · 108 erythrocytes), and 6-
methylmercaptopurine ribonucleotides (6-MMPRs) were very high (11 666 pmol/8 · 108
erythrocytes; therapeutic interval, <5800 pmol/8 · 108 erythrocytes). A second
quantification of thiopurine metabolites 3 months later confirmed these results
(6-TGNs, 127 pmol/8 · 108 erythrocytes; 6-MMPR, 26 304 pmol/8 · 108 erythrocytes).
The patient had an unusual and extremely high thiopurine S-methyltransferase (TPMT)
activity in erythrocytes [61.5 nmol · h-1 · (mL erythrocytes)-1; reference interval,
8.5–15 nmol · h-1 · (mL erythrocytes)-1]. The lack of clinical efficacy for 6-MP, together
with the evidence of pharmacologic resistance, prompted discontinuation of 6-MP
therapy. Thereafter, we administered the tumor necrosis factor-α (TNF-α) antagonist
adalimumab, but we quickly replaced it with infliximab, which has a good clinical
efficacy and safety profile.
- Dervieux T, Boulieu R. Simultaneous determination of 6-thioguanine and methyl 6-
mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin Chem 1998;44:
Questions to Consider
- What is the clinical utility of assessing the TPMT phenotype or genotype?
- What is the rationale for therapeutic drug monitoring of thiopurines?
- What causes of resistance should be considered before switching to another drug class
in patients with apparent thiopurine resistance?
- How can thiopurine treatment be optimized in patients with a very high TPMT
Final Publication and Comments
The final published version with discussion and comments from the experts appears
in the July 2013 issue of Clinical Chemistry, approximately 3-4 weeks after the Student Discussion is posted.
If you are associated with an educational center and would like to receive the cases and
questions 3-4 weeks in advance of publication, please email email@example.com.
AACC is pleased to allow free reproduction and distribution of this Clinical Case
Study for personal or classroom discussion use. When photocopying, please make sure
the DOI and copyright notice appear on each copy.
Copyright © 2013 American Association for Clinical Chemistry